Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT Followed by Anti-BCMA CAR-T vs ASCT Alone in NDMM
NCT06963866Phase 2Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Xuzhou Medical University. Planned start May 2025; status: not yet recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06963866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963866.